GLI1 and cancer: It has been previously reported that overexpressed GLI‐1 is associated with cisplatin resistance [28], the co‐expressed GLI‐1/SOX2 transcript axis is related to TKI‐erlotinib [27], and taxane‐gemcitabine‐drug cancer resistance in prostate and lung cancer [38].